No Correlation between Anti-drug Antibodies and Therapeutic Response in Tunisian Patients with Chronic Inflammatory Diseases Treated by TNF Blockers.

Autor:	Bouden S; Department of Rheumatology, Tunis El Manar University, Tunis, Tunisia., Laadhar L; Department of Immunology, Rabta Hospital, Tunis El Manar University, Tunis, Tunisia., Soua J; Department of Rheumatology, Charles Nicoles Hospital, Tunis El Manar University, Tunis, Tunisia., Ben Messaoud M; Department of Rheumatology, Charles Nicoles Hospital, Tunis El Manar University, Tunis, Tunisia., Rouached L; Department of Rheumatology, Tunis El Manar University, Tunis, Tunisia., Ayadi I; Department of Immunology, Rabta Hospital, Tunis El Manar University, Tunis, Tunisia., Saidane O; Department of Rheumatology, Charles Nicoles Hospital, Tunis El Manar University, Tunis, Tunisia., Ben Tekaya A; Department of Rheumatology, Tunis El Manar University, Tunis, Tunisia., Mahmoud I; Department of Rheumatology, Charles Nicoles Hospital, Tunis El Manar University, Tunis, Tunisia., Rekik S; Department of Immunology, Rabta Hospital, Tunis El Manar University, Tunis, Tunisia., Srairi HS; Department of Rheumatology, Tunis El Manar University, Tunis, Tunisia., Tekaya R; Department of Rheumatology, Charles Nicoles Hospital, Tunis El Manar University, Tunis, Tunisia., Bellakhal S; Department of Internal Medecine, FSI Hospital, Tunis El Manar University, Tunis, Tunisia., Fekih M; Department of Gastro-enterology, Rabta Hospital, Tunis El Manar University, Tunis, Tunisia., Abdelmoula L; Department of Rheumatology, Charles Nicoles Hospital, Tunis El Manar University, Tunis, Tunisia., Kallel M; Department of Immunology, Rabta Hospital, Tunis El Manar University, Tunis, Tunisia.
Jazyk:	angličtina
Zdroj:	Current rheumatology reviews [Curr Rheumatol Rev] 2024; Vol. 20 (4), pp. 435-443.
DOI:	10.2174/0115733971257151230919095431
Abstrakt:	Introduction: Tumor necrosis factor alpha (TNF alpha) blockers such as infliximab (IFX) and adalimumab (ADA) had significantly changed the course of inflammatory diseases such as rheumatoid arthritis (RA), spondyloarthritis (SpA) and Crohn's disease (CD). However, about 30% of patients do not respond to these treatments. This lack of response may be due to the formation of antibodies against these drugs (anti-drug antibodies: ADAbs). The aim of this study was to determine the prevalence of ADAbs against IFX and ADA, and the trough serum concentration of IFX and ADA in RA, SpA or CD patients and to assess their impact on the therapeutic response. Methods: A cross sectional, multi-centric study was conducted, including patients with RA, SpA or CD treated with IFX or ADA as a first biotherapy for at least 6 months. ADAbs and trough levels were measured by an Enzyme Linked Immunosorbent assay (ELISA). Results: 197 patients were included (57 RA, 73 SpA and 67 CD). ADAbs were positive in 40% of cases for IFX and 25% for ADA. They were positive in 40% of SpA, 35% of RA, and 21% of CD. The presence of ADAbs was inversely correlated to the trough levels of IFX and ADA during RA (p = 0.01 and p < 0.0001), SpA (p < 0.01 and p < 0.0001) and CD (p = 0.001 and p = 0.04). For all pathologies, the presence of ADAbs was not correlated with disease activity. Concomitant methotrexate significantly reduced immunogenicity. Conclusion: In our study, the presence of ADAb and low trough levels seem to not affect the therapeutic response in patients on TNF alpha antagonists. Other tracks more than immunogenicity should be investigated to explain the loss of response to these biotherapies. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu